FeesSafety
Pluang+

LKQ investors may claim losses after stock dropped 22% on weak Q3 results and CEO exit.

Market News
16 Nov 2026, 22:05 WIB
GlobeNewsWire
View Source
Bearish
LKQ investors may claim losses after stock dropped 22% on weak Q3 results and CEO exit.

The Rosen Law Firm is investigating a class action lawsuit for LKQ Corporation shareholders following a 22.47% stock drop on October 23, 2026. The decline followed weak third-quarter results and a major executive departure, which allegedly involved misleading business information. Investors who bought LKQ securities may be entitled to compensation without upfront fees. The firm encourages affected shareholders to join the class action to seek recovery of losses.

The story about LKQ Corporation comes with this market snapshot from Pluang's Consumer Cyclical sector as of Nov 17, 2026 02:41 WIB: out of 134 stocks, 26 rose and 108 fell. Notable movers include NIO at USD 2.73 with a 1-day change of -5.86%, QS at USD 3.47 down 5.71%, and CPNG at USD 14.34 down 5.63%. Typical hold times on Pluang range from 39 to 83 days among these stocks.

More News

Disney Q4 outlook strong with 50%+ EPS growth and streaming as key driver

Disney Q4 outlook strong with 50%+ EPS growth and streaming as key driver

Disney's fiscal Q4 report, due November 17, is expected to show strong growth with analysts forecasting over 50% earnings per share (EPS) growth and more than 12% revenue increase. Streaming revenue rose 11% last quarter with margins hitting double d...

Company Fundamentals
Bullish
1 hour ago
Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox has launched a new Australia realm on Amazon Web Services (AWS) in the Sydney region, providing Australian government agencies and enterprises a local option for managing DNS, DHCP, and IP address management (DDI) with enhanced security. Thi...

Market News
Bullish
1 hour ago
European Commission approves RASONQUE for metastatic pancreatic cancer treatment

European Commission approves RASONQUE for metastatic pancreatic cancer treatment

The European Commission has approved RASONQUE (daraxonrasib), the first broad RAS-targeted oral medicine for adults with metastatic pancreatic adenocarcinoma who have had prior systemic therapy. This approval covers patients with or without identifie...

Market News
Bullish
2 hours ago
SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE, a European leader in multi-technical services, has acquired Dutch company Duflex B.V. to enhance its industrial automation, machine building, and robotics capabilities. Duflex, with 26 employees and €8 million revenue in 2025, specializes in ta...

Company Fundamentals
Bullish
3 hours ago
Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel Développement SAS disclosed that it repurchased a total of 3,878 of its own shares between November 9 and November 13, 2026. The average purchase price during this period was approximately €34.67 per share. This buyback is part of an authorized...

Company Fundamentals
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App